CGT4824 / Cogent Biosci - LARVOL DELTA

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire) - "Anticipated Upcoming Milestones:...(i) Initiate a Phase 1 trial of the first Cogent-discovered pipeline program, designed as a potent, selective, reversible FGFR2 inhibitor with best-in-class potential in the second half of 2024; (ii) Select lead candidate and initiate IND-enabling studies from ongoing PI3Kα program, designed to potently and selectively target the H1047R driver mutation, which affects >30,000 cancer patients each year."

New P1 trial • Pipeline update • Preclinical • Oncology

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium (GlobeNewswire) - "Cogent Biosciences...presented updated preclinical data from its potent, selective and brain penetrant ErbB2 inhibitor program along with initial preclinical data from its newly disclosed H1047R mutant-selective PI3Kα inhibitor discovery program at the 2023 San Antonio Breast Cancer Symposium (SABCS)....The poster presented today shows that CGT4255 demonstrated low nM potency against ErbB2 wild-type and oncogenic ErbB2 mutations with 100-fold selectivity over wild-type-EGFR....CGT4824 demonstrated low nM potency in H1047R mutant PI3K cell lines, differentiated dose ascending PK in mice with high bioavailability and low clearance. CGT4824 also showed >95% inhibition of pAKT in a H1047R PD model, importantly without increases in insulin or C-peptide."

Preclinical • Breast Cancer